AXGN logo

Axogen Inc

AXGN

Build a strategy around AXGN

Accountable AI Logo

Axogen Inc AI Insights

Informational only. Not investment advice.
As of 2025-12-17

Snapshot

  • Gross margin 74.8% TTM vs industry median 41.6% - premium pricing power in nerve repair niche with 1.8x advantage[Gross Margin TTM]
  • Revenue 3Y CAGR 17.6% vs industry 0.8% - 22x faster growth while reaching operating profitability (1.8% margin TTM)[Total Revenue 3Y Growth]
  • P/S 7.2x vs industry median 3.0x with negative EPS (-$0.09 TTM) - priced for continued growth execution[P/S Ratio]

Watch Triggers

  • Operating Margin TTM: Sustains above 5% for 2+ quartersConfirms operating leverage thesis; current 1.8% is breakeven territory
  • Total Revenue 3Y Growth: Falls below 10%Growth deceleration invalidates premium valuation; P/S 7.2x requires 15%+ growth
  • Interest Expense TTM: Exceeds operating incomeCurrently $7.8M vs $3.9M op income - already consuming 2x; refinancing risk

Bull Case

Specialty medical device with 75% gross margins in nerve repair - limited competition enables pricing power. 17.6% 3Y revenue CAGR demonstrates market adoption.

Gross Margin TTMTotal Revenue 3Y Growth

Just crossed profitability threshold with $3.9M operating income TTM. Fixed cost base means incremental revenue drops to bottom line at high rate.

Operating Income TTMEBITDA TTM

Bear Case

Valuation demands perfection: P/S 7.2x (2.4x industry), P/B 13.5x, P/CF 237x. Any growth stumble severely punishes stock.

P/S RatioP/B RatioP/CF Ratio

Debt/equity 0.56x with $7.8M interest expense TTM consuming most of $3.9M operating income. Thin margin for error.

Debt to EquityInterest Expense TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
45%

Leverage AXGN's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Operating leverage inflection: path to sustained profitability as revenue scales past fixed cost base

1-3ymed
  • Operating income turned positive at $3.9M TTM
  • R&D 12.7% of revenue - leverage as sales grow
  • Gross margin stable at 75% provides cushion
EBITDA $13.1M TTM vs prior lossesAsset turnover 1.05x above median 0.58xFCF turned positive at $2.1M TTM

Valuation Context

Caveats

Public Strategies Rankings

See how Axogen Inc ranks across different investment strategies.

Leverage AXGN's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.